RPRX

27.54

1.25% 0.34

Handel nachbörslich: 27.01 -0.53 -1.92%

Royalty Pharma Plc (RPRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

$27.20

Offen:

$27.12

24-Stunden-Volumen:

1.81M

Relative Volume:

0.87

Marktkapitalisierung:

$12.34B

Einnahmen:

$2.24B

Nettoeinkommen (Verlust:

$673.24M

KGV:

244.80

EPS:

0.1125

Netto-Cashflow:

$2.67B

1W Leistung:

+1.44%

1M Leistung:

-0.76%

6M Leistung:

-3.06%

1J Leistung:

-1.47%

1-Tages-Spanne:

$26.95

$27.57

1-Wochen-Bereich:

$26.94

$27.59

52-Wochen-Spanne:

$25.20

$31.66

Royalty Pharma Plc Stock (RPRX) Company Profile

Firmenname

Royalty Pharma Plc

Sektor

Healthcare (1182)

Branche

Biotechnology (671)

Telefon

(212) 883-0200

Adresse

110 EAST 59TH STREET, NEW YORK, NY

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

RPRX's Discussions on Twitter

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-06-03	Herabstufung	UBS	Buy → Neutral
2022-06-14	Fortgesetzt	UBS	Buy
2022-05-13	Eingeleitet	Scotiabank	Sector Outperform
2022-04-27	Eingeleitet	Goldman	Buy
2022-04-14	Hochstufung	JP Morgan	Neutral → Overweight
2022-04-06	Fortgesetzt	Morgan Stanley	Overweight
2021-10-29	Hochstufung	Citigroup	Neutral → Buy
2021-07-30	Eingeleitet	Tigress Financial	Buy
2020-11-09	Hochstufung	UBS	Neutral → Buy
2020-07-14	Eingeleitet	Evercore ISI	In-line
2020-07-13	Eingeleitet	BofA Securities	Buy
2020-07-13	Eingeleitet	Citigroup	Neutral
2020-07-13	Eingeleitet	Cowen	Outperform
2020-07-13	Eingeleitet	Goldman	Neutral
2020-07-13	Eingeleitet	JP Morgan	Neutral
2020-07-13	Eingeleitet	Morgan Stanley	Equal-Weight
2020-07-13	Eingeleitet	SunTrust	Buy
2020-07-13	Eingeleitet	UBS	Neutral

Alle ansehen

Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten

05:45 AM

Royalty Pharma (NASDAQ:RPRX) Raised to “Buy” at StockNews.com - Defense World

05:45 AM

04:29 AM

Royalty Pharma plc and Syndax Pharmaceuticals Enter into $350 Million Royalty Funding Agreement for Niktimvo - Marketscreener.com

04:29 AM

02:44 AM

Royalty Pharma (NASDAQ:RPRX) Raised to "Buy" at StockNews.com - MarketBeat

02:44 AM

Nov 04, 2024

Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo - The Manila Times

Nov 04, 2024

Syndax secures $350 million in royalty funding from Royalty Pharma By Investing.com - Investing.com UK

Nov 04, 2024

With 72% ownership, Royalty Pharma plc (NASDAQ:RPRX) boasts of strong institutional backing - Simply Wall St

Nov 04, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by abrdn plc - MarketBeat

Nov 04, 2024

Trend Tracker for (RPRX) - Stock Traders Daily

Nov 04, 2024

Nov 03, 2024

Cannon Global Investment Management LLC Purchases Shares of 34,500 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 03, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Blue Trust Inc. - Defense World

Nov 03, 2024

Nov 01, 2024

Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance

Nov 01, 2024

Royalty Pharma plc (NASDAQ:RPRX) Receives $41.67 Consensus Price Target from Brokerages - Defense World

Nov 01, 2024

Oct 30, 2024

Royalty Pharma (NASDAQ:RPRX) Rating Lowered to Hold at StockNews.com - Defense World

Oct 30, 2024

Royalty Pharma (RPRX) Reports Next Week: Wall Street Expects Earnings Growth - Nasdaq

Oct 30, 2024

Royalty Pharma (RPRX) to Release Earnings on Wednesday - MarketBeat

Oct 30, 2024

Oct 29, 2024

Allspring Global Investments Holdings LLC Reduces Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World

Oct 29, 2024

Signaturefd LLC Lowers Stake in Royalty Pharma plc (NASDAQ:RPRX) - Defense World

Oct 29, 2024

Royalty Pharma plc (NASDAQ:RPRX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Oct 29, 2024

China Universal Asset Management Co. Ltd. Acquires 33,206 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Oct 29, 2024

Oct 28, 2024

Royalty Pharma (NASDAQ:RPRX) Cut to Hold at StockNews.com - MarketBeat

Oct 28, 2024

Oct 25, 2024

Royalty Pharma (NASDAQ:RPRX) Price Target Lowered to $40.00 at Citigroup - MarketBeat

Oct 25, 2024

Raymond James & Associates Purchases 71,402 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Oct 25, 2024

Oct 24, 2024

Keene & Associates Inc. Buys Shares of 19,050 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Oct 24, 2024

Why Southern, Xcel Energy And Royalty Pharma Are Winners For Passive Income - Yahoo Finance

Oct 24, 2024

Oct 22, 2024

Royalty Pharma plc (NASDAQ: RPRX) Drops -1.14% In Early Trade; What Lies Ahead? - Stocks Register

Oct 22, 2024

Oct 20, 2024

3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income - The Motley Fool

Oct 20, 2024

Oct 18, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Marathon Asset Management Ltd - MarketBeat

Oct 18, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Truist Financial Corp - Defense World

Oct 18, 2024

Oct 17, 2024

Paragon Capital Management Inc. Sells 49,241 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Oct 17, 2024

Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024 - The Manila Times

Oct 17, 2024

Oct 15, 2024

Sanctuary Advisors LLC Invests $649,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Oct 15, 2024

Oct 14, 2024

Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Oct 14, 2024

Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21 - Simply Wall St

Oct 14, 2024

How does Royalty Pharma plc (RPRX) change from a tortoise to a hare? - SETE News

Oct 11, 2024

Royalty Pharma announces Q4 dividend of $0.21 per share By Investing.com - Investing.com South Africa

Oct 11, 2024

Royalty Pharma Declares Fourth Quarter 2024 Dividend - ForexTV.com

Oct 11, 2024